De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Savara Toekomstige groei

Future criteriumcontroles 5/6

De verwachting is dat Savara de winst en omzet met respectievelijk 54.2% en 66.4% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 54.5% per jaar.

Belangrijke informatie

54.2%

Groei van de winst

54.5%

Groei van de winst per aandeel

Biotechs winstgroei	28.8%
Inkomstengroei	66.4%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	03 Oct 2024

Recente toekomstige groei-updates

Recent updates

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Aug 26

Savara GAAP EPS of -$0.06 in-line

Aug 11

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Jan 24

Is Savara (NASDAQ:SVRA) A Risky Investment?

Jul 05

Savara: They Failed Once, But They Are Trying Again

Jun 07

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Mar 17

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Feb 26

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

Nov 24

Savara EPS misses by $0.01

Nov 05

Winst- en omzetgroeiprognoses

NasdaqGS:SVRA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	56	-32	-82	N/A	5
12/31/2025	2	-86	-86	N/A	7
12/31/2024	N/A	-85	-79	N/A	7
6/30/2024	N/A	-75	-72	-72	N/A
3/31/2024	N/A	-64	-60	-60	N/A
12/31/2023	N/A	-55	-51	-51	N/A
9/30/2023	N/A	-49	-44	-44	N/A
6/30/2023	N/A	-43	-39	-39	N/A
3/31/2023	N/A	-40	-38	-38	N/A
12/31/2022	N/A	-38	-35	-35	N/A
9/30/2022	N/A	-39	-35	-35	N/A
6/30/2022	N/A	-39	-36	-36	N/A
3/31/2022	N/A	-41	-39	-39	N/A
12/31/2021	N/A	-43	-40	-40	N/A
9/30/2021	0	-45	-43	-43	N/A
6/30/2021	0	-46	-41	-41	N/A
3/31/2021	0	-44	-36	-36	N/A
12/31/2020	0	-50	-43	-40	N/A
9/30/2020	0	-68	-41	-37	N/A
6/30/2020	N/A	-69	-45	-42	N/A
3/31/2020	N/A	-81	-51	-47	N/A
12/31/2019	N/A	-78	-45	-45	N/A
9/30/2019	N/A	-57	-46	-46	N/A
6/30/2019	N/A	-57	-43	-43	N/A
3/31/2019	N/A	-47	-41	-40	N/A
12/31/2018	N/A	-62	-39	-39	N/A
9/30/2018	N/A	-58	-39	-38	N/A
6/30/2018	N/A	-52	-38	-38	N/A
3/31/2018	N/A	-53	N/A	-35	N/A
12/31/2017	N/A	-31	N/A	-28	N/A
9/30/2017	0	-28	N/A	-21	N/A
6/30/2017	0	-25	N/A	-16	N/A
3/31/2017	0	-14	N/A	-9	N/A
12/31/2016	0	-11	N/A	-8	N/A
12/31/2015	0	-9	N/A	-5	N/A
12/31/2014	2	-6	N/A	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat SVRA de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.5% ).

Winst versus markt: Er wordt verwacht dat SVRA de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat SVRA binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van SVRA ( 66.4% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van SVRA ( 66.4% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SVRA naar verwachting over 3 jaar hoog zal zijn

Savara Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 19% to US$10.71

No longer forecast to breakeven

Forecast to breakeven in 2026

No longer forecast to breakeven

Price target increased by 7.3% to US$5.50

Price target increased by 7.5% to US$5.38

Recent updates

Savara Appoints Braden Parker as Chief Commercial Officer

Savara: Trial Successful, But I'm Only Half Convinced

Price target increased by 19% to US$10.71

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Savara Inc. Announces Positive Results from the Pivotal, Phase 3 IMPALA-2 clinical trial

Savara: The Binary Bet On Phase 3 Data

Savara Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Savara Inc., Annual General Meeting, Jun 06, 2024

Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024

No longer forecast to breakeven

New minor risk - Profitability

Chairman & CEO recently sold US$396k worth of stock

Forecast to breakeven in 2026

Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

New minor risk - Profitability

No longer forecast to breakeven

Price target increased by 7.3% to US$5.50

Price target increased by 7.5% to US$5.38

New minor risk - Shareholder dilution

New minor risk - Share price stability

Savara Inc. has completed a Follow-on Equity Offering in the amount of $79.994334 million.

Savara Inc. Completes Enrollment of Pivotal Phase 3 Impala-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis

Independent Director recently bought US$259k worth of stock

No longer forecast to breakeven

Price target increased by 21% to US$4.60

Savara Inc. Announces New Leadership Appointments

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Savara Inc. Announces New Leadership Appointments

Independent Director recently bought US$56k worth of stock

Forecast to breakeven in 2025

Independent Director recently bought US$82k worth of stock

Independent Director recently bought US$68k worth of stock

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Independent Director recently bought US$187k worth of stock

Independent Director recently bought US$142k worth of stock

Savara Announces Resignation of Badrul Chowdhury as Chief Medical Officer, Effective on September 9, 2022

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Savara GAAP EPS of -$0.06 in-line

Independent Director recently bought US$138k worth of stock

Savara Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Savara Inc., Annual General Meeting, Jun 02, 2022

Price target increased to US$4.50

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Independent Director recently bought US$64k worth of stock

Independent Director recently bought US$215k worth of stock

Independent Director recently bought US$176k worth of stock

Independent Director recently bought US$115k worth of stock

Is Savara (NASDAQ:SVRA) A Risky Investment?

Savara Inc. Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

Savara Inc.(NasdaqGS:SVRA) dropped from Russell 3000E Value Index

Savara: They Failed Once, But They Are Trying Again

Independent Director recently bought US$81k worth of stock

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Savara Inc. has completed a Follow-on Equity Offering in the amount of $113.011275 million.

Revenue and earnings beat expectations

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Chairman & CEO recently bought US$50k worth of stock

New 90-day high: US$2.06

New 90-day high: US$1.97

New 90-day high: US$1.57

Price target lowered to US$2.67

Savara Inc. Provides Update on Molgradex in aPAP and the Phase 3 IMPALA 2 Trial

Savara Inc. Announces CEO Change

New 90-day high: US$1.44

Price target lowered to US$3.83

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

New 90-day low: US$1.00